Article Text

Download PDFPDF
PPI-induced hypergastrinaemia and Barrett's mucosa: the fog thickens
  1. Helge Lyder Waldum1,2,
  2. Øyvind Hauso1,2,
  3. Arne Kristian Sandvik1,2
  1. 1Department of Gastroenterology and Liver Diseases, St. Olavs Hospital HF, University Hospital of Trondheim, Trondheim, Norway
  2. 2Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
  1. Correspondence to Dr Helge Lyder Waldum, Department of Gastroenterology, St. Olavs Hospital, Prinsesse Kristinas gt 1, NO-7006 Trondheim, Norway; helge.waldum{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the study by Obszynska and co-workers1 on proton pump inhibitors (PPIs) and Barrett's oesophagus, and the accompanying editorial.2 The background for the study1 was whether PPIs are beneficial or harmful to patients with Barrett's oesophagus. They assessed the risks of PPI treatment by focusing on hypergastrinaemia, the presence of the cholecystokinin 2 (CCK2) receptor in different tissues by immunohistochemistry, and gene expression analysis. Furthermore, they analysed the effect of gastrin on cell lines transfected with the CCK2 receptor.

They found gastrin mRNA expression as expected in the antral mucosa, but also in the normal oesophageal mucosa as well as in Barrett's mucosa. Moreover, CCK2 mRNA expression was found not only in the oxyntic mucosa but also …

View Full Text


  • Linked articles 218776.

  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles

  • PostScript
    Janusz Jankowski Trevor Graham Rebecca Harrison